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Correlation between increased urinary serotonin levels and
coronary artery disease in cigarette smoking patients
Necat YILMAZ1, Yakup MERMERDAŞ2, Esin EREN3, Ayşenur YEĞİN1, Emine NAMIDURU2

Aim: Platelets secrete serotonin (5-hydroxytryptamine), which has several effects on the vascular wall and promotes
thrombogenesis, mitogenesis, and the proliferation of smooth muscle cells. We therefore measured excreted levels of 5hydroxytryptamine (5-HT) concentrations in urine as a means of assessing vascular lesions in patients with coronary
artery disease ( CAD).
Materials and methods: Subjects who underwent coronary angiography were classified into 2 groups according to their
diagnosis. The CAD group consisted of 33 patients with coronary artery stenosis, whereas the healthy control group
consisted of 30 subjects. An isocratic high-performance liquid chromatographic (HPLC) system with an electrochemical
detector was used for the HPLC analysis of serotonin in urine.
Results: The mean urine 5-HT concentration was significantly (P < 0.01) higher in CAD patients than in the healthy
control patients. Interestingly, the excretion of the urinary 5-HT levels in CAD patients were positively associated with
cigarette smoking (r = 0.411, P < 0.01), serum hs-CRP levels (r = 0.198, P < 0.05), and age (r = 0.132, P < 0.05).
Conclusion: The increase in the amount of serotonin in urine in correlation with cigarette smoking, age, and hs-CRP
may be important for future treatment strategies.
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Sigara içen koroner arter hastaları ve artmış idrar serotonin seviyeleri arasındaki
ilişkinin korelasyonu
Amaç: Trombositler serotonin salgılar (5-hydroxytryptamine); bu salgının damar duvarı üzerinde çeşitli etkileri vardır
ve düz kas hücreleri üzerinde mitogenezi, trombogenezi artırıcıdır. Bu sebeble biz koroner arter hastalarındaki (KAH)
vasküler lezyonları değerlendirmek için serotonin'in (5-HT) idrardaki atılım seviyelerini ölçtük.
Yöntem ve gereç: Koroner anjiografi yapılan kişiler teşhislerine göre iki gruba ayrıldı. KAH grubunda koroner arter
stenozu olan 33 hasta vardı. Sağlıklı kontrol grubunda 30 kişi vardı. İzokratik yüksek basınç sıvı kromatoğrafisi (HPLC)
ve elektrokimyasal dedektör idrardaki serotonin ölçümünde kullanıldı.
Bulgular: Sağlıklı kontrollere oranla KAH hasta grubunda idrardaki 5-HT konsantrasyonu anlamlı miktarda yüksekti
(P < 0,01). İlginç olarak, KAH hasta grubunda idrara atılan 5-HT miktarı ile sigara içilmesi (r = 0,411, P < 0,01), serum
hs-CRP (r = 0,198, P < 0,05) ve yaş (r = 0,132, P < 0,05) arasında pozitif korelasyon gözlendi.
Sonuç: İdrara atılan serotonin miktarındaki artışın sigara yaş ve hs-CRP ile korelasyonu gelecekte kullanılacak tedavi
stratejileri için önemli olabilir.
Anahtar sözcükler: Sigara içmek, serotonin, 5-HT, idrar, koroner, trombosit
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Introduction
Serotonin,
chemically
known
as
5hydroxytryptamine (5-HT), is a biogenic monoamine
with a molecular weight of 176 Da. 5-HT, a
decarboxylated derivative of tryptophan, is
synthesized in the enterochromaffin cells and released
into the blood stream to be incorporated into
platelets. At the site of endothelial lesions, platelets
aggregate and secrete 5-HT that presents several
vascular actions involved in thrombosis and
atherogenesis (1). In fact, 5-HT may induce
vasoconstriction in the presence of an endothelial
injury, the aggregation of platelets, and the
mitogenesis of arterial smooth muscle cells and
endothelial cells. The serotonin is released at the site
where platelets are activated, in situations such as
atherosclerotic vascular lesions (2,3).
The pathophysiological mechanisms by which
platelets contribute to the atherosclerotic process are
not fully understood. Low doses of 5-HT dilate the
arteries through stimulation of 5-HT1 receptors, but
high doses elicit vasocontraction by way of
stimulation of the 5-HT2 receptors (4). Experimental
animal studies have demonstrated that platelets are
activated and aggregate at the sites of coronary artery
stenosis and endothelial injury (5). Activated platelets
release serotonin in substantial quantities, causing
vasoconstriction and the recurrent aggregation of
platelets with cyclic flow reductions (1). Serotonin
also acts as a growth factor, stimulating mitogenesis
and the migration of arterial smooth muscle cells.
Furthermore, serotonin has shown it promotes the
proliferation of vascular endothelial cells, and direct
endothelial injury in cell cultures suggests the release
of lactate dehydrogenase and preloaded (14C)adenine when exposed to serotonin (2). Thus,
serotonin clearly has important vascular actions, and
may be involved in atherogenesis as well (3).
Moreover, studies indicate that nicotine increases
serotonin release in the brain, while nicotine
withdrawal has the opposite effect. Some of the
behavioral effects of nicotine, including its reinforcing
efficacy, result, in part, from the activation of
mesolimbic dopamine neurons. Serotonergic neurons
modulate the functioning of dopamine neurons in a
complex fashion. Much of this complexity arises from
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the fact that serotonin (5-HT) exerts its effects
through multiple receptor subtypes, some of which
even act in apparent functional opposition to one
another (6,7).
In this study, we assessed the urinary excretion of
serotonin as a clinical marker of coronary artery
disease in cigarette smoking and non-smoking
subjects with stable symptoms admitted to elective
coronary angiography for chest pain.
Materials and methods
Subjects
All patients referred to the Department of
Cardiology, University of Gaziantep, between March
2007 and May 2007, whose clinical data were available
were included in our study. The CAD group consisted
of 33 patients (7 females and 26 males; mean age 60.54
± 2.16 years) with stenosis of the coronary arteries.
The healthy control group consisted of 30 subjects (8
females and 22 males, mean age 58.95 ± 2.2 years).
Each angiogram was evaluated jointly by at least 2
cardiologists. Coronary artery lesions were magnified,
traced, and measured with calipers to determine the
percentage of diameter narrowing the artery. All
coronary angiographies were performed in the same
center. Coronary artery disease was classified into
groups according to the maximum coronary stenosis
at the angiography: 0%-19% (no detectable CAD),
20%-49% (mild disease), 50%-69% (moderate
disease), and 70%-100% (severe disease). Another
classification of the severity of the disease was
assessed by counting the number of diseased vessels (0
to 3). All subjects were questioned for established
cardiovascular risk factors including diabetes,
smoking, renal disease, and hypertension.
Obesity was defined as a body mass index (BMI)
greater than 27.8 kg/m2 as proposed by the National
Institutes of Health Consensus Statement. Diabetes
mellitus was considered present in patients with a
known history of diabetes and patients with a fasting
blood glucose ≥ 126 mg/dL (7.0 mmol/L) according
to the American Diabetes Association criteria. The
study was approved by the local Ethics Committee,
and the individuals participating in the study gave
their informed consent.
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Blood samples
Fasting blood samples were collected by a standard
venipuncture technique between 08.30 and 11.30. The
blood was taken into K3 EDTA vacutainer tubes for
hemogram and into plain tubes for serum samples.
Serum and plasma were separated after the
centrifugation of the blood at +4 °C, 1500 × g for 10
min and stored at –70 °C until analysis.

We measured urinary 5-HT in the samples using
an HPLC method (8) involving a column-switching
system, including a pretreatment reverse-phase
column (internal diameter of the column 4.6 mm, and
35 mm long), an analytical reverse-phase column
(internal diameter of the column 4.6 mm, and 120
mm long) and a post-column reaction. 5-HT in 500
μL of sample was bound in the pretreatment column
with an eluent containing glycine, sodium
perchlorate, and disodium EDTA. We transferred the
5-HT bound in the pretreatment column to the
analytical column and separated it with an eluent
containing sodium acetate, ammonium nitrate,
acetonitrile, and disodium EDTA. We used a postcolumn reaction, employing benzylamine for the
derived fluorescent reagent, to detect 5-HT in the
HPLC method.
For the HPLC analysis of serotonin in urine and
plasma, an isocratic HPLC system with
electrochemical detector is suitable (Figure).
Accessories for electrochemical detectors were
obtained from Chromsystems® (urine serotonin
normal range: 28.4-125 μmol/day, intra-assay: CV <
2%, inter-assay: CV < 3%, linearity: up to 1000 μg/L,
limit of quantification: 5 μg/L, run time:
approximately 8 min, injection volume: 20 μL,
potential: approximately +400 to +500 mV, internal
standard solution of N-methylserotonin).
Routine laboratory measurements
Routine laboratory investigations were carried out
by using a Roche® autoanalyzer with Roche reagents
(Roche®, Hitachi®, Mannheim/Germany) for serum
creatine, urinary creatine, serum alanine
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Urine collection
Urine samples for the determination of serotonin
and creatine excretion were obtained from a 24-h
urine specimen, including the early morning portion.
After their division into aliquots, the urine samples
were also frozen at –70 °C before assay. Urinary
serotonin concentrations were expressed relative to
the urinary creatinine levels.
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All the subjects identified themselves as either
current smokers (N = 21), or current non-smokers (N
= 12), and were compared by chi-square for CAD. In
addition to this, they were all monitored for somatic
illnesses throughout the investigation period and were
excluded if symptoms of any infectious or systemic
illness were present (i.e. acute or chronic liver disease,
cancer, renal disorder, rheumatic disease, etc).
Patients diagnosed with acute coronary syndrome 6
months prior to the study were excluded. Additional
exclusion criteria included alcohol intake, and the use
of some types of drugs such as antidepressants,
anticonvulsants, estrogen, lipid-lowering therapy, and
other medications that might affect serotonin
metabolism. The subjects were also asked to avoid
these foods containing large amounts of serotonin for
2 days prior to and during specimen collection:
pineapples,
eggplants,
avocados,
bananas,
redcurrants, kiwis, melons, mirabelle, gooseberries,
tomatoes, walnuts, and plums.

Analytical methods

Serotonin

The healthy subjects (n = 30) also had coronary
angiograms, and they underwent a comprehensive
physical examination by a physician, completed the
World Health Organization standard Rose
questionnaire on chest pain, and answered other
questions about their past medical history. All of them
had normal electrocardiograms according to
Minnesota Coding Criteria.
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Figure. Typical chromatogram of urine 5-HT.
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transaminase (ALT), aspartate transaminase (AST),
triglyceride (TG), total cholesterol (TC), HDLcholesterol (HDL-C), uric acid (UA), urea, CK-MB
and platelet (Plt), Hemoglobin (Hb), and WBC
concentrations. Serum hs-CRP levels were
determined by using the Immulite® analyzer with
DPC reagents (Los Angeles, CA, USA).
Statistical analysis
The data were evaluated for all variables (mean ±
SD). The differences between the groups were tested
with a non-paired t-test for continuous variables, and
the categorical variables were examined by Pearson’s
2
χ test for exact values. The difference in the current
smoking frequency between cases and controls was
assessed by Fisher’s exact test. Statistical analysis was
considered significant at P values of 0.05.

Results
The results of our statistical data are given in Table 1.
The table shows the summary statistics obtained for the
patients with CAD and for apparently healthy subjects.
There was no significant difference between the groups
in BMI, waist/hip ratio and age. The mean urinary 5-HT
level in the control group was 28.6 ± 6.9 μmol/mmol of
creatinine, whereas it was 55.1 ± 14 μmol/mmol of
creatinine in the CAD group (P < 0.01). The correlation
between urinary serotonin excretion and CAD was
strengthened when the heavy smoker (> 40/day) patients
(n = 12) or serum hs-CRP levels were included in the
analysis (r = 0.410, P < 0.039 and r = 0.199, P < 0.05
respectively). Urinary serotonin was neither related to
the number of diseased vessels, degree of occlusion, nor
to the other routine measurement results (P > 0.05).

Table 1. Summary statistics of subjects groups (mean ± SD).
Healthy (n = 30)

CAD (n = 33)

Female (%)
Age (year)
Smoking (%)*
Hypertension (n)
Diabetes (n)
BMI (kg/m2)
Waist/Hip ratio (cm/cm)
Urine 5-HT (μmol/ mmol of creatinine) **
Serum creatinine (mg/dL)

40%
58.95 ± 2.2
16%
0
0
24.8 ± 1.74
0.89
28.6 ± 6.9
1.09 ± 0.32

Maximum coronary stenosis

Not detectable

hs-CRP (mg/dL) **
WBC (103/μL)
TC (mg/dL)
TG (mg/dL)
HDL-C (mg/dL) **
UA (mg/dL) *
ALT (U/L) *
AST (U/L) *
CK-MB (U/L) *
Urea (mg/dL)
Plt (103/μL)
Hb (g/dL)
Htc(%)

0.47 ± 0.61
7219 ± 1768
164 ± 42
170 ± 37
43 ± 11.12
5.1 ± 1
21 ± 2.3
20 ± 2.5
11 ± 2.2
35 ± 9.78
252 ± 76.5
13.3 ± 1.6
40.1 ± 4

35%
60.54 ± 2.16
63%
14
11
26.2 ± 1.96
0.95
55.1 ± 14
0.95 ± 0.39
Mild: 14%
Moderate: 42%
Severe: 44%
1.54 ± 0.87
8426 ± 2527
158 ± 42
155 ± 25
31 ± 7.93
6.4 ± 1
37 ± 5.8
34 ± 2.3
44 ± 13
38 ± 17.8
249 ± 64.3
14.2 ± 1.1
41 ± 3

* Healthy versus CAD, P < 0.05, **Healthy versus CAD, P < 0.01
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Table 2. Urinary 5-HT and significant correlation coefficients of
biomarkers of coronary artery disease (Pearson’s
coefficients).

constricts the arteries, and shear stress can be
augmented by the narrowed arteries. Consequently,
athermanous lesions advance (13-16).

Variable

5-HT (urinary serotonin)

Number of cigarettes smoked daily

r = 0.410, P < 0.001

hs-CRP

r = 0.199, P < 0.05

Age

r = 0.132, P < 0.05

Recent evidence points to the role of a
polymorphism in the promoter region of the
serotonin transporter gene in predisposing patients to
depression after stressful life events. Other work has
investigated the possibility that this polymorphism is
common to both altered serotonergic function and
cardiovascular reactivity to stress. A study of
monozygotic and dizygotic twins has provided further
evidence for a genetic risk factor common to both
depression and heart disease (6).

Discussion
This study has shown that urinary 5-HT
concentration is considerably higher in CAD patients
than in healthy control subjects, and it has a strong
association with smoking in CAD patients. In urine,
serotonin excretion was previously evaluated by
HPLC methods with fluorometric or amperometric
detection, and by enzyme immunoassay (4). Normal
values obtained with our method and expressed in
nmol/24 h or in nmol/mmol of creatinine agreed with
those previously described (4). Our sophisticated
chromatographic conditions allowed us to separate
and to quantify 5-HT in urine more definitively.
5-HT affects the peripheral circulation in 2
opposing ways: it constricts the arteries and augments
platelet aggregation by way of 5-HT2 receptors, but it
dilates arteries and inhibits platelet aggregation by
way of 5-HT1 receptors. 5-HT1 receptors are
predominantly distributed on the surfaces of vascular
endothelial cells, which are damaged by many
mechanisms, particularly by shear stress to the
vascular wall and by oxidized low-density lipoprotein
in patients with risk factors for atherosclerosis (9,10).
The vasodilatation is mediated by NO released on
stimulation of 5-HT1B receptors on the vascular
endothelial cells. Therefore, when 5-HT is applied to
the diseased arteries, vasoconstriction instead of
vasodilatation occurs, in vitro and in vivo. The 5-HT
released locally from the activated platelets would
have increased NO release, which would have dilated
the arteries to decrease the shear stress to the vascular
wall and suppressed the platelet activation to restore
the perturbation in the normal vessels. However,
when the endothelial cells are damaged, NO release
may be deficient, enabling 5-HT to reach the vascular
smooth-muscle cells because of deficient barrier
function of the endothelial cells (11,12). Stimulation
of 5-HT2 receptors on the smooth-muscle cells

As an inductor of platelet aggregation and vascular
contraction, 5-HT has been implicated in coronary
artery disease. This is also supported by the observation
that inhibitors of 5-HT re-uptake protect against MI. In
addition, 5-HT stimulates the hyperplasia of artery
smooth muscle, thus contributing to the endothelial
dysfunction that characterizes the pathogenesis of
cardiovascular disease (7). Atherosclerotic lesions are
advanced in patients with CAD and because these
lesions can be confirmed with the use of coronary
angiography. We performed coronary angiography in
all subjects enrolled in this study. Since it is obvious that
atherosclerotic vascular lesions advance with aging, the
increased plasma 5-HT level may have been a result of
the activation of the circulating platelets releasing 5-HT
into the circulation (17). Due to limited information, it
is hard to explain the exact reason why the 5-HT
increased significantly in the urine. Serotonin is
released from nerve terminals and distributed at the
intestinal chromaffin cells, which are taken up into the
platelets. Most likely, the increased 5-HT content in the
urine might mean that the platelets had been activated
or that uptake into the platelets had been impaired
(8,18).
Some of the effects of 5-HT, such as vascular
contraction and platelet aggregation, can lead to
thrombus formation and have been implicated in the
pathogenesis of myocardial infarction (MI).
Moreover, smoking is a well-documented risk factor
for cardiovascular disease, and an increased 5-HT
receptor density among smokers has been described
(7). This fact might explain our results about the
correlation between higher urinary 5-HT levels in
smoking patients.
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Emerging evidence suggests that alterations in
immune functioning and inflammation may contribute
to the development and clinical manifestations of CAD.
The body’s inflammatory response to chronic
hypercholesterolemia and hypertension may contribute
to atherosclerosis as damage to the arterial lining occurs
over time. The increase in hs-CRP levels in our patients
with CAD (Table 1) might be related to this explanation,
and such a correlation has been shown by other
researchers. For example, Ridker et al. showed that
patients who were initially disease free but who
developed peripheral arterial disease over 5 years differed
from the controls by having higher levels of C-reactive
protein after controlling for other risk factors (6).

Several limitations of the study should be pointed
out. First of all, the study sample was relatively small.
Secondly, we have not genotyped a 5-HTTLPR.
Furthermore, the smoking status has not been verified
with the measurement of exhaled CO concentration
of smokers to avoid the classification error attributed
to self-report.
Clinical studies are necessary for further
conclusions. From these findings, we propose that
urinary serotonin may be useful as a marker for CAD.
We have confirmed in this study that urinary 5-HT
concentrations increase in patients with coronary
artery disease.
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